{"id":21356,"date":"2017-06-08T14:00:19","date_gmt":"2017-06-08T14:00:19","guid":{"rendered":"https:\/\/ipo.org\/?p=21356"},"modified":"2017-08-07T17:19:38","modified_gmt":"2017-08-07T17:19:38","slug":"pharma-lessons-ptab-litigation-prosecution","status":"publish","type":"post","link":"https:\/\/ipo.org\/index.php\/pharma-lessons-ptab-litigation-prosecution\/","title":{"rendered":"Pharma Lessons from the PTAB: Litigation and Prosecution\u00a0"},"content":{"rendered":"<div>\n<p paraid=\"1174620371\" paraeid=\"{2ec8ea08-a295-4af0-9529-0ad662022377}{129}\"><span><span xml:lang=\"EN-US\" lang=\"EN-US\"><span>After a slow start, AIA challenges are now a frequent life-or-death risk for biopharmaceutical patents, totaling 212 in 2016, more than twice the number two years earlier. Exemplifying the PTAB\u2019s power was the Federal Circuit\u2019s April decision in<span>\u00a0<\/span><\/span><\/span><i><span xml:lang=\"EN-US\" lang=\"EN-US\"><span>Novartis v.<span>\u00a0<\/span><\/span><\/span><\/i><i><span xml:lang=\"EN-US\" lang=\"EN-US\"><span>Noven<\/span><\/span><\/i><span xml:lang=\"EN-US\" lang=\"EN-US\"><span><span>\u00a0<\/span>that upheld the invalidation by the PTAB of claims covering Novartis\u2019 dementia patch Exelon, even though both the Federal Circuit and Delaware\u2019s federal court had earlier ruled otherwise. Our panelists, all litigators with extensive pharma patent PTAB experience, will spell out winning strategies specific to the industry for both patent owners and challengers, and also will highlight lessons for patent prosecutors that emerge from PTAB practice. Topics to be discussed include:<\/span><\/span><span data-ccp-props=\"{&quot;134233117&quot;:true,&quot;134233118&quot;:true,&quot;201341983&quot;:0,&quot;335559738&quot;:100,&quot;335559739&quot;:100,&quot;335559740&quot;:240}\">\u00a0<\/span><br \/>\n<\/span><\/p>\n<\/div>\n<ul role=\"list\">\n<li data-listid=\"31\" aria-setsize=\"-1\" data-aria-posinset=\"1\" role=\"listitem\" data-aria-level=\"1\"><span xml:lang=\"EN-US\" lang=\"EN-US\"><span>The role of objective indicia of<span>\u00a0<\/span><\/span><\/span><span xml:lang=\"EN-US\" lang=\"EN-US\"><span>nonobviousness<\/span><\/span><span xml:lang=\"EN-US\" lang=\"EN-US\"><span>. Pharma patents do put up a better fight at the PTAB than other technologies: last year, a third of biotech\/pharma claims survived PTAB trials, almost three times the survival rate of electrical\/computer claims;<\/span><\/span><span data-ccp-props=\"{&quot;134233117&quot;:true,&quot;134233118&quot;:true,&quot;201341983&quot;:0,&quot;335559738&quot;:100,&quot;335559739&quot;:100,&quot;335559740&quot;:240}\">\u00a0<\/span><\/li>\n<li data-listid=\"31\" aria-setsize=\"-1\" data-aria-posinset=\"2\" role=\"listitem\" data-aria-level=\"1\"><span xml:lang=\"EN-US\" lang=\"EN-US\"><span>The surge in PGRs challenges to pharma patents on Section 112 grounds of indefiniteness and enablement;<\/span><\/span><span data-ccp-props=\"{&quot;134233117&quot;:true,&quot;134233118&quot;:true,&quot;201341983&quot;:0,&quot;335559738&quot;:100,&quot;335559739&quot;:100,&quot;335559740&quot;:240}\">\u00a0<\/span><\/li>\n<li data-listid=\"31\" aria-setsize=\"-1\" data-aria-posinset=\"3\" role=\"listitem\" data-aria-level=\"1\"><span xml:lang=\"EN-US\" lang=\"EN-US\"><span>The relationship between district court Hatch-Waxman litigation and PTAB challenges;<\/span><\/span><span data-ccp-props=\"{&quot;134233117&quot;:true,&quot;134233118&quot;:true,&quot;201341983&quot;:0,&quot;335559738&quot;:100,&quot;335559739&quot;:100,&quot;335559740&quot;:240}\">\u00a0<\/span><\/li>\n<li data-listid=\"31\" aria-setsize=\"-1\" data-aria-posinset=\"4\" role=\"listitem\" data-aria-level=\"1\"><span xml:lang=\"EN-US\" lang=\"EN-US\"><span>How to inoculate continuations or<span>\u00a0<\/span><\/span><\/span><span xml:lang=\"EN-US\" lang=\"EN-US\"><span>divisionals<\/span><\/span><span xml:lang=\"EN-US\" lang=\"EN-US\"><span><span>\u00a0<\/span>of challenged patents to relevant prior art.<\/span><\/span><span data-ccp-props=\"{&quot;134233117&quot;:true,&quot;134233118&quot;:true,&quot;201341983&quot;:0,&quot;335559738&quot;:100,&quot;335559739&quot;:100,&quot;335559740&quot;:240}\">\u00a0<\/span><\/li>\n<\/ul>\n<div>\n<p paraid=\"1559491435\" paraeid=\"{2ec8ea08-a295-4af0-9529-0ad662022377}{183}\"><span xml:lang=\"EN-US\" lang=\"EN-US\"><span>Speakers:<\/span><\/span><span data-ccp-props=\"{&quot;134233117&quot;:true,&quot;134233118&quot;:true,&quot;201341983&quot;:0,&quot;335559738&quot;:100,&quot;335559739&quot;:100,&quot;335559740&quot;:240}\">\u00a0<\/span><\/p>\n<\/div>\n<ul role=\"list\">\n<li data-listid=\"32\" aria-setsize=\"-1\" data-aria-posinset=\"5\" role=\"listitem\" data-aria-level=\"1\"><span xml:lang=\"EN-US\" lang=\"EN-US\"><span>Eldora Ellison,\u202f<\/span><\/span><i><span xml:lang=\"EN-US\" lang=\"EN-US\"><span>Sterne Kessler Goldstein &amp; Fox, PLLC<\/span><\/span><\/i><span data-ccp-props=\"{&quot;134233117&quot;:true,&quot;134233118&quot;:true,&quot;201341983&quot;:0,&quot;335559738&quot;:100,&quot;335559739&quot;:100,&quot;335559740&quot;:240}\">\u00a0<\/span><\/li>\n<li data-listid=\"32\" aria-setsize=\"-1\" data-aria-posinset=\"6\" role=\"listitem\" data-aria-level=\"1\"><span xml:lang=\"EN-US\" lang=\"EN-US\"><span>Cynthia Lambert Hardman,\u202f<\/span><\/span><i><span xml:lang=\"EN-US\" lang=\"EN-US\"><span>Goodwin Procter LLP<\/span><\/span><\/i><span data-ccp-props=\"{&quot;134233117&quot;:true,&quot;134233118&quot;:true,&quot;201341983&quot;:0,&quot;335559738&quot;:100,&quot;335559739&quot;:100,&quot;335559740&quot;:240}\">\u00a0<\/span><\/li>\n<li data-listid=\"32\" aria-setsize=\"-1\" data-aria-posinset=\"7\" role=\"listitem\" data-aria-level=\"1\"><span xml:lang=\"EN-US\" lang=\"EN-US\"><span>Kerry Taylor,\u202f<\/span><\/span><i><span xml:lang=\"EN-US\" lang=\"EN-US\"><span>Knobbe<\/span><\/span><\/i><i><span xml:lang=\"EN-US\" lang=\"EN-US\"><span>, Martens, Olson &amp; Bear LLP<\/span><\/span><\/i><span data-ccp-props=\"{&quot;134233117&quot;:true,&quot;134233118&quot;:true,&quot;201341983&quot;:0,&quot;335559738&quot;:100,&quot;335559739&quot;:100,&quot;335559740&quot;:240}\">\u00a0<\/span><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>After a slow start, AIA challenges are now a frequent  [&#8230;]<\/p>\n","protected":false},"author":72,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-21356","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Pharma Lessons from the PTAB: Litigation and Prosecution\u00a0 - Intellectual Property Owners Association<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ipo.org\/index.php\/pharma-lessons-ptab-litigation-prosecution\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharma Lessons from the PTAB: Litigation and Prosecution\u00a0 - Intellectual Property Owners Association\" \/>\n<meta property=\"og:description\" content=\"After a slow start, AIA challenges are now a frequent [...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ipo.org\/index.php\/pharma-lessons-ptab-litigation-prosecution\/\" \/>\n<meta property=\"og:site_name\" content=\"Intellectual Property Owners Association\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/IPOAssociation\/\" \/>\n<meta property=\"article:published_time\" content=\"2017-06-08T14:00:19+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2017-08-07T17:19:38+00:00\" \/>\n<meta name=\"author\" content=\"Michael Marion\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@ipo\" \/>\n<meta name=\"twitter:site\" content=\"@ipo\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Michael Marion\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/ipo.org\\\/index.php\\\/pharma-lessons-ptab-litigation-prosecution\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ipo.org\\\/index.php\\\/pharma-lessons-ptab-litigation-prosecution\\\/\"},\"author\":{\"name\":\"Michael Marion\",\"@id\":\"https:\\\/\\\/ipo.org\\\/#\\\/schema\\\/person\\\/b2b29aa393fbb03aea9dab179a9c936e\"},\"headline\":\"Pharma Lessons from the PTAB: Litigation and Prosecution\u00a0\",\"datePublished\":\"2017-06-08T14:00:19+00:00\",\"dateModified\":\"2017-08-07T17:19:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/ipo.org\\\/index.php\\\/pharma-lessons-ptab-litigation-prosecution\\\/\"},\"wordCount\":224,\"publisher\":{\"@id\":\"https:\\\/\\\/ipo.org\\\/#organization\"},\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ipo.org\\\/index.php\\\/pharma-lessons-ptab-litigation-prosecution\\\/\",\"url\":\"https:\\\/\\\/ipo.org\\\/index.php\\\/pharma-lessons-ptab-litigation-prosecution\\\/\",\"name\":\"Pharma Lessons from the PTAB: Litigation and Prosecution\u00a0 - Intellectual Property Owners Association\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ipo.org\\\/#website\"},\"datePublished\":\"2017-06-08T14:00:19+00:00\",\"dateModified\":\"2017-08-07T17:19:38+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ipo.org\\\/index.php\\\/pharma-lessons-ptab-litigation-prosecution\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ipo.org\\\/index.php\\\/pharma-lessons-ptab-litigation-prosecution\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ipo.org\\\/index.php\\\/pharma-lessons-ptab-litigation-prosecution\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/ipo.org\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pharma Lessons from the PTAB: Litigation and Prosecution\u00a0\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ipo.org\\\/#website\",\"url\":\"https:\\\/\\\/ipo.org\\\/\",\"name\":\"Intellectual Property Owners Association\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/ipo.org\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ipo.org\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/ipo.org\\\/#organization\",\"name\":\"Intellectual Property Owners Association\",\"url\":\"https:\\\/\\\/ipo.org\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/ipo.org\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/ipo.org\\\/wp-content\\\/uploads\\\/2019\\\/06\\\/ipo_logo.png\",\"contentUrl\":\"https:\\\/\\\/ipo.org\\\/wp-content\\\/uploads\\\/2019\\\/06\\\/ipo_logo.png\",\"width\":570,\"height\":226,\"caption\":\"Intellectual Property Owners Association\"},\"image\":{\"@id\":\"https:\\\/\\\/ipo.org\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/IPOAssociation\\\/\",\"https:\\\/\\\/x.com\\\/ipo\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/ipoassociation\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/ipo.org\\\/#\\\/schema\\\/person\\\/b2b29aa393fbb03aea9dab179a9c936e\",\"name\":\"Michael Marion\",\"description\":\"1819\",\"sameAs\":[\"https:\\\/\\\/ipo.org\"],\"url\":\"https:\\\/\\\/ipo.org\\\/index.php\\\/author\\\/michael-309\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pharma Lessons from the PTAB: Litigation and Prosecution\u00a0 - Intellectual Property Owners Association","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ipo.org\/index.php\/pharma-lessons-ptab-litigation-prosecution\/","og_locale":"en_US","og_type":"article","og_title":"Pharma Lessons from the PTAB: Litigation and Prosecution\u00a0 - Intellectual Property Owners Association","og_description":"After a slow start, AIA challenges are now a frequent [...]","og_url":"https:\/\/ipo.org\/index.php\/pharma-lessons-ptab-litigation-prosecution\/","og_site_name":"Intellectual Property Owners Association","article_publisher":"https:\/\/www.facebook.com\/IPOAssociation\/","article_published_time":"2017-06-08T14:00:19+00:00","article_modified_time":"2017-08-07T17:19:38+00:00","author":"Michael Marion","twitter_card":"summary_large_image","twitter_creator":"@ipo","twitter_site":"@ipo","twitter_misc":{"Written by":"Michael Marion","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ipo.org\/index.php\/pharma-lessons-ptab-litigation-prosecution\/#article","isPartOf":{"@id":"https:\/\/ipo.org\/index.php\/pharma-lessons-ptab-litigation-prosecution\/"},"author":{"name":"Michael Marion","@id":"https:\/\/ipo.org\/#\/schema\/person\/b2b29aa393fbb03aea9dab179a9c936e"},"headline":"Pharma Lessons from the PTAB: Litigation and Prosecution\u00a0","datePublished":"2017-06-08T14:00:19+00:00","dateModified":"2017-08-07T17:19:38+00:00","mainEntityOfPage":{"@id":"https:\/\/ipo.org\/index.php\/pharma-lessons-ptab-litigation-prosecution\/"},"wordCount":224,"publisher":{"@id":"https:\/\/ipo.org\/#organization"},"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/ipo.org\/index.php\/pharma-lessons-ptab-litigation-prosecution\/","url":"https:\/\/ipo.org\/index.php\/pharma-lessons-ptab-litigation-prosecution\/","name":"Pharma Lessons from the PTAB: Litigation and Prosecution\u00a0 - Intellectual Property Owners Association","isPartOf":{"@id":"https:\/\/ipo.org\/#website"},"datePublished":"2017-06-08T14:00:19+00:00","dateModified":"2017-08-07T17:19:38+00:00","breadcrumb":{"@id":"https:\/\/ipo.org\/index.php\/pharma-lessons-ptab-litigation-prosecution\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ipo.org\/index.php\/pharma-lessons-ptab-litigation-prosecution\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ipo.org\/index.php\/pharma-lessons-ptab-litigation-prosecution\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ipo.org\/"},{"@type":"ListItem","position":2,"name":"Pharma Lessons from the PTAB: Litigation and Prosecution\u00a0"}]},{"@type":"WebSite","@id":"https:\/\/ipo.org\/#website","url":"https:\/\/ipo.org\/","name":"Intellectual Property Owners Association","description":"","publisher":{"@id":"https:\/\/ipo.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ipo.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/ipo.org\/#organization","name":"Intellectual Property Owners Association","url":"https:\/\/ipo.org\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ipo.org\/#\/schema\/logo\/image\/","url":"https:\/\/ipo.org\/wp-content\/uploads\/2019\/06\/ipo_logo.png","contentUrl":"https:\/\/ipo.org\/wp-content\/uploads\/2019\/06\/ipo_logo.png","width":570,"height":226,"caption":"Intellectual Property Owners Association"},"image":{"@id":"https:\/\/ipo.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/IPOAssociation\/","https:\/\/x.com\/ipo","https:\/\/www.linkedin.com\/company\/ipoassociation\/"]},{"@type":"Person","@id":"https:\/\/ipo.org\/#\/schema\/person\/b2b29aa393fbb03aea9dab179a9c936e","name":"Michael Marion","description":"1819","sameAs":["https:\/\/ipo.org"],"url":"https:\/\/ipo.org\/index.php\/author\/michael-309\/"}]}},"_links":{"self":[{"href":"https:\/\/ipo.org\/index.php\/wp-json\/wp\/v2\/posts\/21356","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ipo.org\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ipo.org\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ipo.org\/index.php\/wp-json\/wp\/v2\/users\/72"}],"replies":[{"embeddable":true,"href":"https:\/\/ipo.org\/index.php\/wp-json\/wp\/v2\/comments?post=21356"}],"version-history":[{"count":1,"href":"https:\/\/ipo.org\/index.php\/wp-json\/wp\/v2\/posts\/21356\/revisions"}],"predecessor-version":[{"id":21357,"href":"https:\/\/ipo.org\/index.php\/wp-json\/wp\/v2\/posts\/21356\/revisions\/21357"}],"wp:attachment":[{"href":"https:\/\/ipo.org\/index.php\/wp-json\/wp\/v2\/media?parent=21356"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ipo.org\/index.php\/wp-json\/wp\/v2\/categories?post=21356"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ipo.org\/index.php\/wp-json\/wp\/v2\/tags?post=21356"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}